LXRX
$1.62
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
Intraday
Recent News
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 5, 2026, H.C. Wainwright raised the price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $6 from $4 previously and maintained a Buy rating following the company’s fourth-quarter report. H.C. Wainwright increased the probability of success for pilavapadin […]
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
Lexicon Pharmaceuticals Q4 Earnings Call Highlights
Lexicon Pharmaceuticals (NASDAQ:LXRX) outlined progress across three late-stage programs and reported sharply lower operating expenses during its fourth-quarter and full-year 2025 earnings call held March 5, 2026. Management emphasized near-term regulatory and clinical milestones for sotagliflozin i
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Lexicon Pharmaceuticals, Inc.'s Q4 2025 earnings call
Lexicon (LXRX) Q4 2025 Earnings Call Transcript
Joining me today are Dr. Michael S. Exton, Lexicon Pharmaceuticals, Inc.'s Chief Executive Officer and Director; Dr. Craig B. Granowitz, Senior Vice President and Chief Medical Officer; and Scott M. Coiante, Senior Vice President and Chief Financial Officer. This morning, Lexicon Pharmaceuticals, Inc. issued a press release announcing our financial results for the fourth quarter and full year of 2025, which is available on our website at www.lexpharma.com and through our SEC filings.